PIP-101 / Shorla Oncology - LARVOL DELTA

Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States (Businesswire) - "Shorla Oncology...today announced it has entered into a licensing agreement and strategic partnership with a U.K.-based innovative drug development and manufacturing company. Under the terms of the agreement, Shorla will obtain an exclusive license from the developer to register and commercialize PIP-101, the first palatable oral solution of the related chemotherapeutic agent in the U.S....Under the terms of the agreement, the developer will continue to manufacture PIP-101. Once Shorla has obtained approval of its New Drug Application (NDA), the company will be responsible for the timely launch, commercialization and sales of PIP-101 in the U.S."

Licensing / partnership • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology